Nicotinamide adenine dinucleotide (NAD+) is the shared substrate that couples sirtuin enzymes to DNA repair and chromatin maintenance. This article reviews how experimental models link NAD+ homeostasis to sirtuin-mediated genomic stability, and where the evidence remains preclinical.

NAD+ as a shared metabolic currency

NAD+ occupies an unusual position in cell biology: it is both a redox coenzyme that shuttles electrons through central metabolism and a consumable substrate for a family of signalling enzymes. Reviews of NAD+ biology describe how the same molecule serves oxidation–reduction reactions while also being cleaved by sirtuins, poly(ADP-ribose) polymerases (PARPs) and the NADase CD38, each of which removes NAD+ from the pool during their catalytic cycle.¹ Because these enzymes do not simply bind NAD+ but degrade it, their combined activity sets the size of the available pool at any moment.

A consistent observation across model organisms is that tissue and cellular NAD+ concentrations decline with age, and that this decline has been associated experimentally with cognitive changes, metabolic dysfunction and reduced cellular resilience in rodents.¹ The research question this article examines is narrower: when NAD+ becomes scarce, what happens to the sirtuin-dependent machinery that helps maintain an intact genome? To follow that thread, it helps first to see why sirtuins are so tightly bound to NAD+ supply.

How sirtuins couple NAD+ to genome maintenance

Sirtuins are NAD+-dependent deacylases: each catalytic turnover consumes one molecule of NAD+, cleaving it into nicotinamide and O-acetyl-ADP-ribose while removing an acetyl group from a target protein. This stoichiometric dependence means that sirtuin output is directly sensitive to NAD+ availability, unlike enzymes that merely require NAD+ as a recyclable cofactor.¹ Among the seven mammalian sirtuins, SIRT1 and SIRT6 are the two most often connected to nuclear genome maintenance in the literature.

The clearest genetic evidence comes from SIRT6. In a foundational study, mice lacking SIRT6 developed profound genomic instability and a set of degenerative, aging-like abnormalities, dying at roughly four weeks of age; the authors linked SIRT6 to base-excision repair and to resistance against DNA damage.³ Subsequent reviews have catalogued SIRT6 substrates spanning DNA-damage repair, telomere integrity and chromatin organisation, positioning the enzyme as a node whose loss produces both genomic and metabolic phenotypes in animal models.⁸⁹ SIRT1, for its part, deacetylates histones and repair-associated factors and participates in the DNA-damage response, though much of the mechanistic detail is drawn from cultured cells.⁶

The logical consequence is that any process lowering NAD+ should, in principle, blunt SIRT1 and SIRT6 activity and therefore weaken the repair and chromatin functions they support. That inference is central to the "NAD+ homeostasis regulates genomic stability" hypothesis, and it is best supported where NAD+ depletion and sirtuin loss produce overlapping phenotypes rather than by direct measurement of repair kinetics as a function of NAD+ concentration in intact tissue.

The NAD+-consuming enzymes at a glance

The table underscores a structural feature of the system: repair-supporting sirtuins share their substrate with enzymes whose activity rises during damage and inflammation. That overlap is where competition begins.

CD38, PARP1 and competition for a shrinking pool

Because NAD+ is finite within a cell, enzymes that consume it interact indirectly through the shared pool. A computational model of the DNA-damage response formalised this idea for SIRT1 and PARP1, proposing that heightened PARP1 activity can lower SIRT1 function by depleting common NAD+ supplies—a form of competitive inhibition operating through metabolite availability rather than direct binding.⁶ When DNA breaks activate PARP1 for immediate strand-break sensing, the model implies a transient reallocation of NAD+ away from sirtuin-dependent processes.

CD38 adds a second, more chronic drain. Work in mice established CD38 as a principal driver of the age-related NAD+ decline, showing that CD38 expression and activity rise with age and that CD38 is required for both NAD+ loss and downstream mitochondrial dysfunction through a SIRT3-dependent mechanism.² The same study identified CD38 as a major degrader of the NAD+ precursor nicotinamide mononucleotide, meaning CD38 can limit not only NAD+ itself but the substrates used to regenerate it.²

In inflammatory settings, CD38 induction becomes pronounced. In a gout model, monosodium urate crystals induced CD38 in macrophages with accompanying NAD+ depletion, and pharmacological CD38 inhibition both restored NAD+ and dampened NLRP3 inflammasome activation while increasing anti-inflammatory SIRT3–SOD2 activity.⁷ Read together, these studies describe a plausible circuit in which chronic inflammatory or genotoxic stress elevates NAD+ consumption, leaving less substrate for the sirtuins that support genome and mitochondrial maintenance. The circuit is well characterised in specific models; whether the same quantitative trade-off governs genomic stability in every chronic disease context is not established.

Mitochondrial consequences: SIRT3, SOD2 and oxidative stress

Genomic stability cannot be separated from redox state, and NAD+ links the two through the mitochondrial sirtuin SIRT3. SIRT3 deacetylates superoxide dismutase 2 (SOD2, or MnSOD), the principal enzyme that detoxifies mitochondrial superoxide. In a myocardial ischaemia–reperfusion model, a SIRT3–SOD2 axis modulated mitochondrial reactive oxygen species and autophagic flux, and genetic ablation of SIRT3 removed the protective effect—direct evidence that SIRT3 activity shapes oxidative-stress handling in vivo.¹⁰ Because SIRT3, like its nuclear relatives, depends on NAD+, a fall in mitochondrial NAD+ would be expected to reduce SOD2 deacetylation and permit greater superoxide accumulation.

The CD38 knockout data reinforce this: restoring NAD+ by removing CD38 improved mitochondrial function through SIRT3 in aged mice.² Elevated mitochondrial oxidant load matters for the genome because reactive oxygen species themselves generate oxidative DNA lesions, adding to the repair burden precisely when sirtuin-supported repair capacity may be constrained. This creates a self-reinforcing loop in the reviewed models—NAD+ scarcity, weaker SIRT3 output, more oxidative damage—although the strength of that loop varies with tissue and stressor.

Salvage flux, proteostasis and autophagy

Cells replenish NAD+ largely through the salvage pathway, in which nicotinamide phosphoribosyltransferase (NAMPT) recycles nicotinamide back toward NAD+. This salvage route is the dominant source of NAD+ in most mammalian tissues, so its regulation effectively governs how much substrate the sirtuins receive.¹ In studies of fatty-liver disease, NAMPT-centred salvage capacity and NAD+ precursor supplementation influenced hepatic NAD+ content and mitochondrial function, illustrating how salvage flux ties into broader metabolic outcomes—while also showing that the relationship is context-dependent.¹¹

NAD+ also connects to the cell's quality-control systems through autophagy. A classic study demonstrated that the NAD+-dependent deacetylase SIRT1 regulates autophagy: SIRT1 forms complexes with, and can deacetylate, the autophagy proteins ATG5, ATG7 and ATG8, and SIRT1-null cells fail to fully activate autophagy under starvation, with SIRT1-deficient mice showing accumulation of damaged organelles.⁴ Later work confirmed SIRT1-dependent deacetylation of ATG5, ATG7 and BECN1 as part of autophagy activation.⁵

The implication is mechanistically coherent: if NAD+ falls, SIRT1 deacetylase output declines, and autophagy—including the clearance of damaged mitochondria—may be impaired, allowing dysfunctional organelles and their oxidant output to persist. This chain of reasoning is supported at each individual link by the cited studies, but the composite claim that NAD+ decline drives mitophagy failure in chronic human disease remains an extrapolation rather than a demonstrated endpoint. Researchers assembling NAD+-focused experiments frequently pair the coenzyme with mitochondrial-derived peptides such as MOTS-c to probe these bioenergetic intersections.

NAD+/NADH redox balance and metabolic plasticity

Beyond its role as a consumable substrate, NAD+ functions as a redox couple with NADH, and the NAD+/NADH ratio reports on the cell's oxidative state. This ratio influences the direction and rate of central metabolic reactions and is often used experimentally as a readout of metabolic state.¹ A shift toward a more reduced ratio constrains reactions that require NAD+ as an electron acceptor, which can limit the flexibility with which a cell moves between glycolysis and oxidative phosphorylation.

This redox dimension intersects with the sirtuin story because the same enzymes reading NAD+ as a signalling substrate are embedded in a network whose electron-carrier balance is shifting simultaneously. In chronic disease models, a depressed NAD+/NADH ratio is frequently reported alongside reduced sirtuin activity, though the two are difficult to disentangle causally because both track overall NAD+ abundance. Treating the ratio as a stand-alone biomarker of "resilience" therefore oversimplifies a system in which redox balance, salvage flux and enzymatic consumption move together.

Evidence, limitations and open questions

Taken as a whole, the literature supports a mechanistically plausible model: NAD+ homeostasis sets the operating budget for sirtuins, and sirtuins—especially SIRT6 and SIRT1—contribute to DNA repair, chromatin maintenance and autophagic quality control. The strongest single pillar is genetic: SIRT6-null mice show genomic instability and premature degeneration.³ The competition logic among sirtuins, PARPs and CD38 is well documented in defined systems.²⁶⁷

The limitations are equally important. Much of the evidence is preclinical—knockout mice, isolated macrophages, cardiomyocyte injury models and in-vitro deacetylation assays. Bridging studies that manipulate NAD+ and then measure genomic-stability endpoints directly in intact tissue are comparatively rare, and human data on NAD+ precursors have shown only modest effects to date.¹¹ These gaps define an active research programme rather than a settled account.

All Qovigen peptides are sold for laboratory and research use only (RUO). Not for human or veterinary use, diagnosis, or treatment.